最新消息
News

其他消息

At Bened Biomedical, our purpose is to help people with brain disorders to have happier lives.
Bened Biomedical signed a deal with a major player in Australian and New Zealand markets
The world’s unique Psychobiotic PS128™ will reach the Balkans.
【賀】精神益生菌PS128®榮獲『美國專利認證』
PS128®牽手Nuvanta前進馬來西亞市場!
益福生醫榮獲錦獅獎:亞太精準醫療年度益生菌全球領導品牌獎
PS128® 前進新加坡-與保健品領導品牌Activhealth® 合作推出兩支新品
快樂小星星計畫將於2018/12/31圓滿落幕!
【賀】精神益生菌PS128®榮獲『中國專利認證』
精神益生菌PS128® 進軍南非市場
益福生醫參與SupplySide West 2018 - Las Vegas
NutraIngredients: Use your head, follow your gut: Bened Biomedical's award-winning probiotic product set for market expansion
精神益生菌PS128®進軍法國-益福生醫與Synergia SAS簽訂合作協議
「精神益生菌PS128®」榮獲Nutra Ingredients-Asia Awards「年度最佳益生菌產品」大獎
精神益生菌PS128®榮獲「2018台北生技獎-新創技術獎」肯定
【賀】精神益生菌PS128®再度榮獲『中華民國專利認證』
益福生醫榮獲台灣科技部TIEC前進矽谷補助
PS128® “Smart Kids Probiotics” Product to be Launched in Hong Kong
益福生醫「精神益生菌株PS128®」榮獲第14屆國家新創獎
【賀】精神益生菌PS128®榮獲『韓國專利認證』
【賀】精神益生菌 PS128® 榮獲日本與歐盟十四國專利
益福生醫榮獲新創企業世界大賽(Startup World Cup)台灣區冠軍
益福生醫獲第六屆女性創業菁英賽「新創組」冠軍
新創公司益福生醫與英國OptiBiotix Health簽署策略合作協議
益福生醫榮獲亞洲育成協會2017 AABI火炬國際化獎
調整體質益生菌K56榮獲中華民國專利
陽明大學蔡英傑教授:2017年是自閉症醫學研究突破年
益福生醫參與第一屆國際菌-腸-腦軸線研討會
輕盈益生菌K21獲中華民國與美國專利
亞洲首次精神益生菌改善自閉症孩童行為效的臨床研究啟動
益福生醫與日、韓大廠簽訂精神益生菌國際產業合作協議
精神益生菌 PS128 獲中華民國專利
2015.11.18~2015.11.22 WPAIC 2015世界精神醫學會國際大會

Bened Biomedical signed a deal with a major player in Australian and New Zealand markets

2020 / 03 / 02

An exclusive deal on PS128™ has been signed between Bened and BioCeuticals, Australia’s leading provider of nutritional and therapeutic supplements, also a practitioner-only brand of the Blackmores Group.

PS128™, a unique Lactobacillus plantarum strain, has been demonstrated to boost dopamine and serotonin in the brain in vivo. During a meeting organized by the office of Austrade in Taipei, PS128™ raised the interest of BioCeuticals for its capability to reduce oxidative stress and attenuate behavioral conditions in children. After the approval and the publication of two clinical studies confirming the efficiency of PS128™ on humans, the Group decided to move into action through this exclusive contract.

The Blackmores Group is one of the biggest suppliers of vitamins and supplements in the region, with both consumer and practitioner brands. The Group’s BioCeuticals brand supplies health professionals with practitioner-only, therapeutic supplements. The Group generated over 300M USD sales revenues in 2017.

“Bened Biomedical is glad to supply the Blackmores Group, including BioCeuticals, with custom PS128™ finished products. The Blackmores Group is a true key player in Asia. With its exclusive PS128™ probiotic products, the Group will be able to help more people,” commented Alain Delpy, head of international business development for Bened Biomedical.

The PS128™ products will be licensed to multiple Blackmores Group family brands including BioCeuticals, Blackmores, and beyond.

“The multi-brand exclusive licensing agreement will allow the Blackmores Group to greatly increase the penetration rate and market potential for PS128™ in the Australian and New Zealand markets. We are very pleased to see PS128™ now available in all major continents in the world,” said Frankie Cheng, the CEO of Bened Biomedical.